Chronic Kidney Disease

Catch up on the guideline updates, trial news, and featured content from March 2026.

Further CONFIDENCE analyses support safe combination therapy in CKD, with improved responses in key patient subgroups.

New OPTN data shows kidney transplant gains from race-free GFR and restored wait times stall, as structural barriers still limit equitable listing access.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

Garimella discusses the history, clinical impact, and rationale for removing race-based GFR from clinical decision-making.

REMODEL reveals how semaglutide protects kidneys, showing reduced inflammation, improved vascular health, and evidence of structural repair in diabetic CKD.

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

Experts discuss major advances in glomerular disease research and care, including molecular technologies, biomarker discovery, APOL1-mediated kidney disease, and evolving clinical trial design and endpoints.

Neuen reflects on new FIND-CKD data suggesting finerenone’s benefit in nondiabetic chronic kidney disease and highlights urgency of early screening and combination therapy.

Data from 39 kidney biopsies may challenge longterm beliefs about diabetic nephropathy in CKD.

Should clinicians consider neighborhood disadvantage the same way they measure proteinuria and GFR for kidney health?

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies

Allocating lower but acceptable quality kidneys to high-risk patients could introduce equity.

Phase 3 FIND-CKD shows finerenone slows non-diabetic CKD decline by improving eGFR slope; Bayer prepares FDA filing for expanded use.

New CKD therapies and a cardiometabolic care model are reshaping kidney disease management.

Experts discuss gaps in CKD detection, the role of albuminuria testing, and the need for earlier, risk-based care to improve outcomes.

7 experts come together to address neighborhood disadvantage and its impact on kidney health in the latest Crisis Point.

Yu, MD, Adler, MD, share their perspectives from a cohort study on in-sequence, and out of sequence paired kidneys transplants.

Salvatore Viscomi, MD on closing CKD health disparities through community testing, AI equity, and accessible care for underserved populations.

Having a primary care provider may be associated with reduced emergency department utilization for patients with ESKD receiving dialysis, according to new research.

An economic model suggest using lower quality, but acceptable kidneys for older adults may be cost efficective and clinically valuable.

Brown discusses a destigmatised future of obesity management in patients with kidney failure.

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.